FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2792289907> ?p ?o ?g. }

• W2792289907 endingPage "324" @default.
• W2792289907 startingPage "316" @default.
• W2792289907 abstract "Purpose To analyze the impact of postmastectomy radiation therapy (PMRT) for patients with T1-T2 tumors and 1 to 3 positive lymph nodes enrolled on the Breast International Group (BIG) 02-98 trial. Methods and Materials The BIG 02-98 trial randomized patients to receive adjuvant anthracycline with or without taxane chemotherapy. Delivery of PMRT was nonrandomized and performed according to institutional preferences. The present analysis was performed on participants with T1-T2 breast cancer and 1 to 3 positive lymph nodes who had undergone mastectomy and axillary nodal dissection. The primary objective of the present study was to examine the effect of PMRT on risk of locoregional recurrence (LRR), breast cancer–specific survival, and overall survival. Results We identified 684 patients who met the inclusion criteria and were included in the analysis, of whom 337 (49%) had received PMRT. At 10 years, LRR risk was 2.5% in the PMRT group and 6.5% in the no-PMRT group (hazard ratio 0.29, 95% confidence interval 0.12-0.73; P = .005). Lower LRR after PMRT was noted for patients randomized to receive adjuvant chemotherapy with no taxane (10-year LRR: 3.4% vs 9.1%; P = .02). No significant differences in breast cancer–specific survival (84.3% vs 83.9%) or overall survival (81.7% vs 78.3%) were observed according to receipt of PMRT. Conclusion Our analysis of the BIG 02-98 trial shows excellent outcomes in women with T1-T2 tumors and 1 to 3 positive lymph nodes found in axillary dissection. Although PMRT improved LRR in this cohort, the number of events remained low at 10 years. In all groups, 10-year rates of LRR were relatively low compared with historical studies. As such, the use of PMRT in women with 1 to 3 positive nodes should be tailored to individual patient risks. To analyze the impact of postmastectomy radiation therapy (PMRT) for patients with T1-T2 tumors and 1 to 3 positive lymph nodes enrolled on the Breast International Group (BIG) 02-98 trial. The BIG 02-98 trial randomized patients to receive adjuvant anthracycline with or without taxane chemotherapy. Delivery of PMRT was nonrandomized and performed according to institutional preferences. The present analysis was performed on participants with T1-T2 breast cancer and 1 to 3 positive lymph nodes who had undergone mastectomy and axillary nodal dissection. The primary objective of the present study was to examine the effect of PMRT on risk of locoregional recurrence (LRR), breast cancer–specific survival, and overall survival. We identified 684 patients who met the inclusion criteria and were included in the analysis, of whom 337 (49%) had received PMRT. At 10 years, LRR risk was 2.5% in the PMRT group and 6.5% in the no-PMRT group (hazard ratio 0.29, 95% confidence interval 0.12-0.73; P = .005). Lower LRR after PMRT was noted for patients randomized to receive adjuvant chemotherapy with no taxane (10-year LRR: 3.4% vs 9.1%; P = .02). No significant differences in breast cancer–specific survival (84.3% vs 83.9%) or overall survival (81.7% vs 78.3%) were observed according to receipt of PMRT. Our analysis of the BIG 02-98 trial shows excellent outcomes in women with T1-T2 tumors and 1 to 3 positive lymph nodes found in axillary dissection. Although PMRT improved LRR in this cohort, the number of events remained low at 10 years. In all groups, 10-year rates of LRR were relatively low compared with historical studies. As such, the use of PMRT in women with 1 to 3 positive nodes should be tailored to individual patient risks." @default.
• W2792289907 created "2018-03-29" @default.
• W2792289907 creator A5008682671 @default.
• W2792289907 creator A5011862433 @default.
• W2792289907 creator A5012187098 @default.
• W2792289907 creator A5012452403 @default.
• W2792289907 creator A5021116939 @default.
• W2792289907 creator A5025394073 @default.
• W2792289907 creator A5027201197 @default.
• W2792289907 creator A5036344172 @default.
• W2792289907 creator A5040290360 @default.
• W2792289907 creator A5045792102 @default.
• W2792289907 creator A5053893264 @default.
• W2792289907 creator A5057557133 @default.
• W2792289907 creator A5067552665 @default.
• W2792289907 creator A5072021902 @default.
• W2792289907 creator A5078571816 @default.
• W2792289907 creator A5081663693 @default.
• W2792289907 creator A5084183478 @default.
• W2792289907 creator A5084707141 @default.
• W2792289907 date "2018-06-01" @default.
• W2792289907 modified "2023-10-18" @default.
• W2792289907 title "Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial" @default.
• W2792289907 cites W1770259999 @default.
• W2792289907 cites W1910241730 @default.
• W2792289907 cites W1948261638 @default.
• W2792289907 cites W1974963414 @default.
• W2792289907 cites W2012535393 @default.
• W2792289907 cites W2036934183 @default.
• W2792289907 cites W2046826982 @default.
• W2792289907 cites W2060250348 @default.
• W2792289907 cites W2062298610 @default.
• W2792289907 cites W2083094100 @default.
• W2792289907 cites W2102607007 @default.
• W2792289907 cites W2125835228 @default.
• W2792289907 cites W2129825983 @default.
• W2792289907 cites W2130840692 @default.
• W2792289907 cites W2131341595 @default.
• W2792289907 cites W2133865595 @default.
• W2792289907 cites W2138652241 @default.
• W2792289907 cites W2140978771 @default.
• W2792289907 cites W2147833901 @default.
• W2792289907 cites W2161871715 @default.
• W2792289907 cites W2162407486 @default.
• W2792289907 cites W2162852953 @default.
• W2792289907 cites W2163221626 @default.
• W2792289907 cites W2168517539 @default.
• W2792289907 cites W2170058000 @default.
• W2792289907 cites W2332829713 @default.
• W2792289907 cites W2521999419 @default.
• W2792289907 cites W2602991407 @default.
• W2792289907 cites W2611369172 @default.
• W2792289907 cites W2617862980 @default.
• W2792289907 cites W2742282063 @default.
• W2792289907 cites W2770195530 @default.
• W2792289907 doi "https://doi.org/10.1016/j.ijrobp.2018.01.105" @default.
• W2792289907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29534902" @default.
• W2792289907 hasPublicationYear "2018" @default.
• W2792289907 type Work @default.
• W2792289907 sameAs 2792289907 @default.
• W2792289907 citedByCount "44" @default.
• W2792289907 countsByYear W27922899072018 @default.
• W2792289907 countsByYear W27922899072019 @default.
• W2792289907 countsByYear W27922899072020 @default.
• W2792289907 countsByYear W27922899072021 @default.
• W2792289907 countsByYear W27922899072022 @default.
• W2792289907 countsByYear W27922899072023 @default.
• W2792289907 crossrefType "journal-article" @default.
• W2792289907 hasAuthorship W2792289907A5008682671 @default.
• W2792289907 hasAuthorship W2792289907A5011862433 @default.
• W2792289907 hasAuthorship W2792289907A5012187098 @default.
• W2792289907 hasAuthorship W2792289907A5012452403 @default.
• W2792289907 hasAuthorship W2792289907A5021116939 @default.
• W2792289907 hasAuthorship W2792289907A5025394073 @default.
• W2792289907 hasAuthorship W2792289907A5027201197 @default.
• W2792289907 hasAuthorship W2792289907A5036344172 @default.
• W2792289907 hasAuthorship W2792289907A5040290360 @default.
• W2792289907 hasAuthorship W2792289907A5045792102 @default.
• W2792289907 hasAuthorship W2792289907A5053893264 @default.
• W2792289907 hasAuthorship W2792289907A5057557133 @default.
• W2792289907 hasAuthorship W2792289907A5067552665 @default.
• W2792289907 hasAuthorship W2792289907A5072021902 @default.
• W2792289907 hasAuthorship W2792289907A5078571816 @default.
• W2792289907 hasAuthorship W2792289907A5081663693 @default.
• W2792289907 hasAuthorship W2792289907A5084183478 @default.
• W2792289907 hasAuthorship W2792289907A5084707141 @default.
• W2792289907 hasConcept C121608353 @default.
• W2792289907 hasConcept C126322002 @default.
• W2792289907 hasConcept C143998085 @default.
• W2792289907 hasConcept C168563851 @default.
• W2792289907 hasConcept C207103383 @default.
• W2792289907 hasConcept C2776802502 @default.
• W2792289907 hasConcept C2777649267 @default.
• W2792289907 hasConcept C2777757722 @default.
• W2792289907 hasConcept C44249647 @default.
• W2792289907 hasConcept C509974204 @default.
• W2792289907 hasConcept C530470458 @default.
• W2792289907 hasConcept C71924100 @default.

• next